Get started

Trend Lines

Garuda: Riding the Momentum WaveFrom February to late May 2025, the stock of GARUDA was trading in a sideways consolidation range, roughly between ₹100 (support) and ₹115-₹120 (resistance). The recent powerful green candles have shattered the upper boundary of this range. Also, the most significant event on the daily chart is the decisive breakout from a descending trendline that had capped prices. Also, LL and HH formation observed on daily chart. The breakout was accompanied by a significant spike in volume ( 862.88K shares ), which is substantially higher than the average volume during the consolidation period. High volume on a breakout lends strong credibility to the move. The RSI is at a strong 69.20 . It is in bullish territory and rising, indicating strong buying momentum. It is approaching the overbought region (>70), but is not there yet, leaving room for further upside before becoming extended. If the stock consolidates above the ₹120-₹121 support level. Buyers step in on any minor dip till ₹118 , and the price then continues its upward trajectory towards the resistance targets of ₹129 and subsequently ₹149 . Disclaimer: This technical analysis is for informational purposes only and should not be considered as financial advice. Trading in the stock market involves risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.
NSE:GARUDALong
by NiftyNotion
Positional or longterm opportunity in CESCGo Long @ 139.6 for Targets of 165, 185.8, and 276.5 with SL 124.2 Reasons to go Long : 1. On a Weekly timeframe if we draw the Fibonacci retracement tool from the recent swing low (point A) to the recent swing high (point B) then we see stock took support from the 0.618 Fibonacci level. 2. Besides, a bullish candlestick pattern Bullish Engulfing (marked with orange) is formed around the 0.618 Fibonacci level. 3. Also there is a strong Trendline (marked with green color) which earlier was acting like resistance but now is providing support to the stock.
NSE:CESCLong
by Nimish_Ghagare
LODHA:Triple Confluence Zone - Fib, Horizontal & Channel SupportHey Traders! NSE:LODHA is showing a compelling bullish structure on the 4H chart — backed by clean price action, structure, and strong confluence. Technical Breakdown: ✅ Ascending Channel: The stock has been consistently respecting its upward-sloping channel since March, forming a sequence of higher highs and higher lows. ✅ Fibonacci Retest: The recent retracement found strong support around the 0.5 and 0.618 zone (₹1,352), aligning with both the horizontal support and the lower channel line. ✅ Horizontal Support: The zone around ₹1,352–₹1,375 (a previous resistance) acted as a strong support during the pullback. Price bounced cleanly from it — confirming its importance. ✅ Confluence: The lower channel support, horizontal support, and Fibonacci level all align in the same area — boosting the reliability of this bounce. Trade Setup: Entry Zone: ₹1,435 (Around current levels) Stop-loss: Below ₹1,328 (Closing Basis) Target: ₹1,700 (upper channel boundary) Reward-to-Risk: 1:2.5 Disclaimer: This analysis is for educational purposes only. Please do your own research and use proper risk management. Thanks for reading! If you liked the setup, drop a comment or a like! Looking forward to hearing your thoughts. Happy Trading! — Anantesh
NSE:LODHALong
by Ananteshm
MTNL's Comeback Story: Innovation and GrowthRevitalizing MTNL: A Bright Future Ahead Target: ₹200 Time frame: 3 years Mahanagar Telephone Nigam Limited (MTNL), a Public Sector Undertaking (PSU), has faced significant challenges in recent years, leading to a decline in its business fortunes. However, despite being knocked out of the competitive telecom market, the company is poised for a resurgence. Embracing New Frontiers As the telecom landscape evolves, MTNL is gearing up to tap into emerging opportunities. The future holds immense promise, and the company is strategically repositioning itself to capitalize on newer forms of communication and technology. 5G: The Game-Changer A key catalyst for MTNL's revival is the ongoing testing of 5G technology. With its potential to enable faster data speeds, lower latency, and greater connectivity, 5G is expected to revolutionize the telecom sector. MTNL's foray into 5G will enable it to offer cutting-edge services, bolstering its competitive edge. Ambitious Targets Three-Year Roadmap Over the next three years, MTNL will concentrate on: Enhancing its 5G capabilities to deliver high-speed, reliable connectivity Developing innovative services and solutions to cater to emerging customer needs Strengthening its network infrastructure to support growing demand Fostering strategic partnerships to drive growth and expansion With a clear vision and robust strategy in place, MTNL is poised to reclaim its position as a leading player in the Indian telecom sector. The future indeed looks bright for this PSU, as it embarks on a transformative journey to reclaim its glory.
NSE:MTNLLong
by liondewarangal
2
PPLPHARMA: 8 Month Slopping Downwards Trendline BreakoutNSE:PPLPHARMA : This Pharma Stock Broke Out of Its Descending Triangle Prison Price Action: - Current Price: ₹216.22 (as of July 15, 2025) - 52-week Range: ₹181.73 - ₹307.90 - The stock has been in a clear descending triangle pattern since November 2024 - Price has been consistently making lower highs while finding support around the ₹190-200 zone - Recent price action shows signs of consolidation near the apex of the triangle Volume Spread Analysis: - Average daily volume: 4.68M shares - Volume spikes were observed during significant price movements in November 2024 and March 2025 - Recent volume has been relatively subdued, indicating a lack of conviction in either direction - Volume pattern suggests an accumulation phase with periodic distribution Key Technical Levels: Support Levels: - Primary Support: ₹190-200 (multiple tests, strong base) - Secondary Support: ₹181.73 (52-week low) - Psychological Support: ₹175-180 zone Resistance Levels: - Immediate Resistance: ₹230-240 (descending trendline) - Secondary Resistance: ₹250-260 (previous swing high) - Major Resistance: ₹280-290 (November 2024 high) Base Formation: - The stock has formed a solid base between ₹190-220 over the past 4 months - This base represents a potential accumulation zone for institutional investors - The horizontal support at ₹200 has been tested multiple times, showing its significance Technical Patterns: - Primary Pattern: Descending Triangle - Secondary Pattern: Potential Cup and Handle formation if the stock breaks above ₹240 - The descending triangle spans approximately 8 months, making it a significant pattern Trade Setup: Entry Strategy: - Breakout Entry: Buy above ₹240 with volume confirmation - Support Entry: Buy near ₹200-205 for swing trade - Conservative Entry: Wait for weekly close above ₹245 for momentum play Exit Levels: - Short-term Target: ₹260-270 - Medium-term Target: ₹290-300 - Long-term Target: ₹350-380 Stop-Loss Levels: - For breakout trades: ₹225 (below breakdown level) - For support trades: ₹185 (below 52-week low) - Trailing stop: 8-10% below entry price Position Sizing: - Risk per trade: Maximum 2% of portfolio - For ₹240 entry with ₹225 stop: Position size = (Portfolio × 0.02) / 15 - Suggested allocation: 1-2% of total portfolio for this trade Risk Management: - Maximum holding period: 3-6 months - Review position if stock fails to break ₹240 within 4 weeks - Partial profit booking at ₹270 (book 50% position) - Trail stop-loss after first target achievement Sectoral and Fundamental Backdrop: Sectoral Analysis: - The India Pharmaceutical Market size is estimated at USD 66.66 billion in 2025, and is expected to reach USD 88.86 billion by 2030, at a CAGR of 5.92% during the forecast period (2025-2030) - India's pharmaceutical industry ranks third globally in pharmaceutical production by volume and 14th by value, supported by a well-established domestic sector comprising approximately 3,000 drug companies and over 10,000 custom manufacturing units - The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA - The biosimilars market in India is expected to grow at a CAGR of 22%, reaching USD 12 billion by 2025, representing nearly 20% of the country's pharmaceutical market Company Fundamentals: - Market Cap: 28,745 Crore (up 42.2% in 1 year), Revenue: 9,151 Cr, Profit: 91.1 Cr - Stock is trading at 3.53 times its book value - The company has a low interest coverage ratio, Promoter Holding: 34.94% - The P/E ratio of Piramal Pharma Ltd is 324 times as on 15-July-2025, a 651% premium to its peers' median range of 33.45 times Business Overview: - The company has a 49% ownership interest in a joint venture with Allergan India Pvt. Ltd (Avvyie, a US pharmaceutical company, holds a 51% ownership interest), which is one of the leading pharmaceutical companies in Ophthalmology formulations in India - Strong presence in glaucoma and dry eye treatments - Diversified portfolio across multiple therapeutic areas Analyst Targets: - Recent research reports show an average share price target of 253 - The estimated share price target for 2025 can range from ₹198 to ₹350 Investment Thesis: Bullish Factors: - Strong sectoral tailwinds with the Indian pharma market growing at 5.92% CAGR - Solid base formation indicating institutional accumulation - Reasonable valuation compared to growth prospects - Strategic partnership with Allergan provides a competitive advantage Risk Factors: - A high P/E ratio indicates expensive valuation - A low interest coverage ratio suggests financial stress - Regulatory changes in the pharmaceutical sector My Take: NSE:PPLPHARMA presents a mixed technical picture with a descending triangle pattern Breakout but strong support base. The stock is at a crucial juncture where a breakout above ₹240 could lead to significant upside, while a breakdown below ₹190 would confirm further weakness. Given the positive sectoral outlook and the company's strategic positioning, a breakout trade above ₹240 with proper risk management offers favorable risk-reward ratio. Keep in the Watchlist. NO RECO. For Buy/Sell. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FOLLOW for more 👍BOOST if you found it useful. ✍️COMMENT below with your views. Meanwhile, check out my other stock ideas on the right side until this trade is activated. I would love your feedback. Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER." This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:PPLPHARMALong
by Karanshah137
19